Navigation Links
Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus
Date:3/11/2008

BOSTON, March 11 /PRNewswire/ -- Replikins, Ltd. has announced development of a chemically synthesized vaccine specific to a Taura Syndrome virus structure based on its patented Replikins(TM) technology. When the vaccine was administered orally to shrimp, 91% survived a challenge by the lethal Taura virus. The specificity of the protective effect was established in control groups by chemically blocking the active regions in the vaccine, and as a result the protective effect was lost in these control groups. The effectiveness of this vaccine, and its rapid production cycle (7 days), represent an important proof of concept for developing vaccines against a range of rapidly replicating high lethality virus outbreaks.

For counteracting emerging infectious disease, early detection and rapid response are critical. Replikin contributions to date are both in early detection and rapid response: 1) Advance warning previously was not possible until it was found in H5N1 influenza that an increase in the virus replikin concentration signalled one year in advance that the outbreak was coming, and indicated the country in which this would occur (FluForecast(TM), Indonesia). 2) The production of vaccines by other methods has required 3 to 12 months, by which time the epidemic may have come and gone, or the vaccine effectiveness reduced or lost because the target changed due to mutation. In contrast, the replikins vaccine found effective here was manufactured synthetically in 7 days.

Viruses lethal to shrimp have been responsible for large losses to aquaculture worldwide. Replikins is forming a division to focus on these viruses. The company is also pursuing development of synthetic vaccine products based on replikin epitopes, Syntopes(TM), for the control of fish hemorrhagic viruses and other lethal aquatic microorganisms,

Contact: Replikins Ltd., 38 The Fenway, Boston MA 02215. email: sbogoch@replikins.com Tel: 646-320-5910 http://www.Replikins.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
2. Vaccinogens New Anti-Cancer Vaccine Commercially Available in Europe This Year
3. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
4. Combination vaccine protects monkeys from ebola and Marburg viruses
5. Nasal Vaccine for Smallpox Confers High Levels of Immunity Without Safety Risks
6. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
7. GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral)
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Vaccinex Antibody Licensed to GlaxoSmithKline
10. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
11. NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, announced today that ... denied its petition to review decisions by ... Patent No. 6,258,540 (",540 Patent") are not patent eligible ... Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  In ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):